Heather Bresch, Mylan’s chief operating officer, has called for an end of the “abuse” of the 180 day generic exclusivity period by brand manufactures that launch a competitor during this period.
Bresch was testifying before the US House of Representatives Judiciary Subcommittee on Courts and Competition Policy, where she reiterated Mylan’s belief that brand manufactures releasing authorised generics “upsets the natural balance of incentives”.
She added: "Congress has an opportunity to act now to ensure that timely access to affordable generics is offered to patients by restoring the true 180-day exclusivity period.
“This is even more profound and critical today as Congress deliberates on a regulatory pathway for life-saving generic biologics, treatments that can cost hundreds of thousands of dollars per patient per year."
The complete speech can be found here . A Wordle of the speech, with a word’s size depicting its frequency of use, is pictured below.